ASN 002

Drug Profile

ASN 002

Alternative Names: ASN002

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator Asana BioSciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours
  • Preclinical Atopic dermatitis; Rheumatoid arthritis

Most Recent Events

  • 16 Mar 2017 Asana BioSciences plans a randomised, double-blind, placebo-controlled, multiple dose escalation phase I trial for Atopic dermatitis in USA
  • 16 Mar 2017 Asana BioSciences files an IND application with the US FDA for Atopic dermatitis
  • 16 Mar 2017 US FDA accepts an IND application for ASN 002 for Atopic dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top